MTA1, a Novel ATP Synthase Complex Modulator, Enhances Colon Cancer Liver Metastasis by Driving Mitochondrial...

Area of Science:

• Oncology
• Cancer Metabolism
• Molecular Biology

Background:

• Liver metastasis is a critical factor in colon cancer mortality.
• The Warburg effect is challenged by observed increases in oxidative phosphorylation (OXPHOS) in cancer, with unclear mechanisms.
• Metastasis-associated antigen 1 (MTA1) role in cancer progression is being investigated.

Purpose of the Study:

• To identify novel modulators of mitochondrial bioenergetic metabolism in colon cancer liver metastasis.
• To elucidate the mechanism by which MTA1 influences oxidative phosphorylation (OXPHOS) and cancer progression.
• To explore therapeutic strategies targeting MTA1 and mitochondrial pathways for colon cancer treatment.

Main Methods:

• Identification of MTA1 as an adenosine triphosphate (ATP) synthase modulator interacting with ATP synthase F1 subunit alpha (ATP5A).
• Assessment of MTA1's role in mitochondrial bioenergetic metabolism reprogramming and OXPHOS enhancement.
• High-throughput drug screening and validation in xenograft models and clinical cases.

Main Results:

• MTA1 facilitates colon cancer liver metastasis by enhancing OXPHOS through ATP synthase modulation.
• MTA1 knockout sensitizes colon cancer cells to drugs targeting mitochondrial metabolism and mTOR inhibitors.
• Inhibition of ATP5A enhances sensitivity to sirolimus in liver-metastasized colon cancer, dependent on MTA1.

Conclusions:

• MTA1 is a novel modulator of mitochondrial bioenergetic reprogramming in cancer metastasis.
• Upregulation of mitochondrial OXPHOS, orchestrated by MTA1, represents a reversal of the Warburg effect in metastasis.
• Targeting MTA1 and ATP5A presents a promising therapeutic avenue for treating colon cancer liver metastasis.